华仁药业(300110.SZ)公告称，公司收到持股5%以上股东华仁世纪集团的减持计划告知函，华仁世纪集 团计划自公告之日起十五个交易日后的三个月内，通过集中竞价交易方式减持不超过公司总股本1%的 股份，即不超过11,822,100股。 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-035 华仁药业股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 一、担保情况概述 华仁药业股份有限公司（以下或"公司"）于2025年4月21日召开第八届董事 会第七次会议，并于2025年5月14日召开2024年度股东大会，审议通过了《关于 向银行申请综合授信及公司对子公司、子公司对公司提供担保的议案》，同意公 司为子公司融资提供额度共计不超过人民币（或等值外币）100,000万元的连带 责任保证担保，其中为子公司安徽恒星制药有限公司（以下简称"安徽恒星"） 提供不超过20,000万元的担保额度，担保额度的有效期自2024年度股东大会审议 通过之日起至2025年度股东大会召开前一日止。具体内容详见公司于2025年4月 23日在巨潮资讯网（www.cninfo.com.cn）披露的《关于向银行申请综合授信及公 司对子公司、子公司对公司提供担保的公告》（公告编号：2025-017）。 二、担保进展情况 近日，公司与合肥科技农村商业银行股份有限公司包河支行签订 ...

关于完成法定代表人变更并换发营业执照的公告 华仁药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、基本情况 华仁药业股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日召开第八届 董事会第八次（临时）会议，审议通过了《关于补选第八届董事会董事长及战略 委员会主任委员的议案》，同意选举张力先生为公司第八届董事会董事长，任期 至第八届董事会任期届满之日止。根据《公司法》《公司章程》的有关规定，将 由张力先生担任公司的法定代表人。具体内容详见公司 2025 年 4 月 29 日在巨潮 资讯网（http://www.cninfo.com.cn）披露的《关于董事长、董事辞职及补选董事 长、战略委员会主任委员暨法定代表人变更的公告》（公告编号：2025-026）。 近日，公司完成了法定代表人的工商变更登记手续，并取得了青岛市市场监 督管理局换发的《营业执照》。 证券代码：300110 证券简称：华仁药业 公告编号：2025-034 2、统一社会信用代码：91370200706426601X 3、企业类型：股份有限公司（上市、自然人投资或控 ...

北京植德（青岛）律师事务所 关于华仁药业股份有限公司 2024 年度股东大会的 法律意见书 植德青（会）字[2025]0001 号 二〇二五年五月 山东省青岛市崂山区香岭路 1 号资源博雅广场 4 号楼 10 层 邮编：266000 10th Floor, Building 4, Resources Boya Plaza, No.1 Xiangling Road, Laoshan District, Qingdao City, Shandong Province 266000 P.R.C www.meritsandtree.com 北京植德（青岛）律师事务所 关于华仁药业股份有限公司 2024 年度股东大会的 法律意见书 植德青（会）字[2025]0001 号 致：华仁药业股份有限公司（华仁药业/贵公司） 北京植德（青岛）律师事务所（以下简称"本所"）接受贵公司的委托，指 派律师出席并见证贵公司 2024 年度股东大会（以下简称"本次会议"）。 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-033 华仁药业股份有限公司 2024 年度股东大会决议公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载，误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无变更、否决提案的情况； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开及召集情况 1、会议通知情况：华仁药业股份有限公司（以下简称"公司"）于2025年4 月23日在巨潮资讯网披露了《关于召开2024年度股东大会的通知》（公告编号： 2025-022），并于2025年4月29日在巨潮资讯网披露了《关于2024年度股东大会 增加提案的公告暨召开2024年度股东大会的补充通知》（公告编号：2025-028）。 2、会议召开时间： （1）现场会议召开时间：2025年5月14日14:00。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025年5月14日上午9:15-9:25，9:30-11:30和下午13:00-15:00；通过深圳证 券交易所互联网投票系统投票的具体时间为：2025年5月14日上午9:15-下午15: ...

华仁药业股份有限公司 章 程 二〇二五年五月 | 第一章 | 总则 1 | | --- | --- | | 第二章 | 经营宗旨和范围 2 | | 第三章 | 股份 2 | | | 第一节 股份发行 2 | | 第二节 | 股份增减和回购 3 | | | 第三节 股份转让 4 | | 第四章 | 股东和股东大会 5 | | | 第一节 股东 5 | | | 第二节 股东大会的一般规定 9 | | | 第三节 股东大会的召集 11 | | | 第四节 股东大会的提案与通知 12 | | | 第五节 股东大会的召开 14 | | | 第六节 股东大会的表决和决议 17 | | 第五章 | 董事会 22 | | | 第一节 董事 22 | | | 第二节 董事会 26 | | 第六章 | 总裁及其他高级管理人员 32 | | 第七章 | 监事会 34 | | | 第一节 监事 34 | | | 第二节 监事会 35 | | 第八章 | 党建工作 36 | | 第一节 | 党组织的机构设置 36 | | 第二节 | 公司党委 37 | | 第三节 | 公司纪委 38 | | 第九章 | 财务会计制度、利润分配和审计 ...

Group 1: Company Development Strategy - The company focuses on transforming and upgrading its development strategy, enhancing core competitiveness through quality, brand, variety, specifications, and dosage forms [1] - Continuous investment in R&D, with a total of CNY 234 million invested over the past three years, aiming to enrich the product matrix and enhance sustainable development capabilities [3] - The company has developed a comprehensive product line including 109 varieties and 223 specifications of drugs, as well as 37 Class II and 37 Class I medical devices [3] Group 2: Financial Performance and Shareholder Value - The company plans to consider share repurchase based on market conditions, financial status, and development strategy, ensuring compliance with disclosure obligations [1][5] - The management is committed to improving operational quality and investment value to enhance shareholder returns [5] - The company achieved profitability in Q1 2025, indicating a positive outlook for future development [12] Group 3: Debt Management and Risk Control - The company has established a debt resolution framework with China National Pharmaceutical Group, allowing for debt repayment through equity and asset compensation [8][12] - Continuous strengthening of internal controls and audit mechanisms to mitigate historical risks and enhance compliance [8][13] - The company is actively pursuing legal measures to recover debts and ensure the execution quality of debt resolution plans [9][11] Group 4: Innovation and Product Development - The company emphasizes the integration of raw materials, formulations, medical devices, and health products to create a comprehensive pharmaceutical ecosystem [6] - It aims to enhance product lifecycle and maintain competitive advantages in the chemical drug sector through consistent evaluation and innovation [6] - The company has obtained a total of 545 authorized patents, reflecting its commitment to innovation [3]

证券代码：300110 证券简称：华仁药业 公告编号：2025-032 华仁药业股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司青岛华仁医疗用 品有限公司收到山东省药品监督管理局核准签发的"一次性滑移垫"的《医疗器械注 册证》，现将相关情况公告如下： 8、注册分类：Ⅱ类 9、批准日期：2025 年 4 月 23 日 10、有效期至：2030 年 4 月 22 日 一、医疗器械基本情况 1、注册人名称：青岛华仁医疗用品有限公司 2、注册人住所：青岛市崂山区株洲路 187 号 3、生产地址：青岛市崂山区株洲路 187 号无菌医疗器械车间楼 4、产品名称：一次性滑移垫 5、型号、规格：I 型、Ⅱ型、Ш 型、Ⅳ型、V 型、Ⅵ型 6、适用范围：用于医疗机构运送、移动患者用 7、注册证编号：鲁械注准 20252150222 二〇二五年五月六日 二、医疗器械相关情况 公司本次获得二类医疗器械注册证的一次性滑移垫用于医疗机构运送、移动 患者用，产品包含 6 个型号规格 ...

Group 1 - Major shareholders of *ST WanFang plan to reduce their holdings by up to 9,341,596 shares, accounting for 3% of the company's total share capital from May 27 to August 25, 2025 [1] - Shareholders of Airo Energy intend to reduce their holdings by up to 800,000 shares, 800,000 shares, and 1,600,000 shares, representing 0.50%, 0.50%, and 1% of the company's total share capital respectively during the same period [1] - Anner plans to reduce its holdings by up to 3,186,159 shares, which is 1.5% of the company's total share capital, from May 27 to August 26, 2025 [1] Group 2 - Shareholders of Chuhuan Technology plan to reduce their holdings by up to 2,395,605 shares, accounting for 3% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [1] - Major shareholder of Dalian Technology intends to reduce their holdings by up to 4,189,336 shares, which is 0.99% of the company's total share capital from May 27 to August 26, 2025 [2] - Dongwei Technology's board members plan to reduce their holdings by a total of 2,574,857 shares, representing 0.8629% of the company's total share capital during the same period [2] Group 3 - Gann Li Pharmaceutical's shareholder has completed a reduction of 6,010,622 shares, which is 1% of the company's total share capital from April 22 to April 30, 2025 [2] - Guanshi Technology's board members plan to reduce their holdings by up to 359,375 shares, accounting for 0.4891% of the company's total share capital from May 27 to August 26, 2025 [2] - Guoguang Electric's shareholder has completed a reduction of 1,625,751 shares, which is 1.5% of the company's total share capital from April 25 to April 30, 2025 [2] Group 4 - Haili Biological's major shareholder has completed a reduction of 13,113,244 shares, representing 2% of the company's total share capital from April 15 to April 22, 2025 [3] - Hengfeng Information's board member has completed a reduction of 198,717 shares, which is 0.1207% of the company's total share capital on April 28, 2025 [3] - Hongwei Technology's shareholder plans to reduce their holdings by up to 820,000 shares, accounting for 0.39% of the company's total share capital from May 12 to August 11, 2025 [3] Group 5 - Huatai Medical's vice president has completed a reduction of 29,943 shares, which is 0.0308% of the company's total share capital from April 28 to April 29, 2025 [4] - Jilin Carbon Valley's major shareholder has completed a reduction of 4,989,160 shares, representing 0.8490% of the company's total share capital from April 25 to April 29, 2025 [4] - Jiahua Technology's shareholder plans to reduce their holdings by up to 1,160,000 shares, accounting for 1.50% of the company's total share capital from May 28 to August 25, 2025 [4] Group 6 - Jiangbo Long's shareholder plans to reduce their holdings by up to 4,159,815 shares, which is 1% of the company's total share capital from May 27 to August 26, 2025 [5] - Jiangshan Co. plans to reduce its holdings in Jiangtian Chemical by 4,330,800 shares, accounting for 3% of its total share capital from May 27 to August 26, 2025 [5] - Kairun Co.'s major shareholder plans to reduce their holdings by up to 9,000,000 shares, representing 2.43% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [5] Group 7 - Lianqi Technology's shareholders plan to reduce their holdings by a total of 18,717,374 shares, which is 2.96% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [9] - Zhongke Information's board members have completed a reduction of 698,914 shares, representing 0.2358% of the company's total share capital [9] - Zhongshi Co.'s major shareholder plans to reduce their holdings by up to 1,800,000 shares, accounting for 1.1527% of the company's total share capital from May 27 to August 26, 2025 [10]

Group 1 - National Integrated Circuit Industry Fund plans to reduce its stake in Jiangbolong by no more than 4,159,815 shares, accounting for 1.00% of the total share capital, between May 27, 2025, and August 26, 2025 [1] - The reduction is due to the fund's operational management needs and will be executed through centralized bidding at market prices [1] - The implementation of this reduction plan will not lead to a change in the company's control or significantly impact its governance structure and ongoing operations [1] Group 2 - Haitai Weiye has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue no more than 710.52 million overseas listed ordinary shares [2] - The listing will take place on the main board of the Hong Kong Stock Exchange, but the matter still carries uncertainties [2] Group 3 - Fudan Zhangjiang announced a price reduction of at least 35% for its Doxorubicin Liposome Injection starting May 1, 2025, which is expected to negatively impact sales revenue [3] - The drug generated approximately RMB 210 million in sales for the year 2024, representing 29% of the company's total sales revenue [3] - The price adjustment may lead to a risk of single product loss for the drug in 2025 [3] Group 4 - Xinyuan Technology's director expressed inability to guarantee the authenticity and completeness of the 2024 annual report and related financial documents, citing significant issues identified by the audit firm [4] - The company has received a notice of investigation from the securities regulatory authority, and the audit report issued was unable to express an opinion [4] Group 5 - ST Xinchao announced that its stock will be suspended from trading starting May 6, 2025, due to the inability to disclose the audited 2024 annual report and the 2025 Q1 report within the legal timeframe [5] - If the company fails to disclose the 2024 annual report within two months of the suspension, it will face delisting risk warnings [5] Group 6 - Huakang Clean has pre-won a project worth RMB 167 million [6] - Tongguang Cable has pre-won a procurement project from the State Grid valued at RMB 142 million [6] - Fengmao Co. has increased its investment in a production base in Thailand to RMB 26 million [6] Group 7 - Huaren Pharmaceutical's wholly-owned subsidiary has obtained a medical device registration certificate for wound dressings [7] Group 8 - Major shareholders of Kairun Co. plan to reduce their holdings by no more than 9 million shares [10] - CITIC Securities has completed its reduction plan for China Gold [10] - The reduction plan for Hengfeng Information's director and vice president has been completed [10]